Slide 1: Cover letter to stock exchanges: Presentation and Video Recording of Q1 FY25 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/SP/2024-25/67 August 10, 2024 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Cor
Slide 2: Q1FY25 Earnings Call
Biocon Limited Q1FY25 Earnings Call 09 - A U G U S T - 2 0 2 4 The Multiplier Effect MAXIMIZING VALUE
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the call concerning the future growth prospects of the Company may be forward-looking statements, which are subject to number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in s
Slide 4: Group CEO Opening Remarks
Group CEO Opening Remarks
Slide 5: Opening Remarks: Q1 FY25 Performance Overview
Opening Remarks: Q1 FY25 Performance Overview Strong performance on a reported basis, driven by the impact of the Eris Lifesciences business transfer consummation Underlying Group Financial performance relatively subdued; inline with expectations and previous guidance Mix of headwinds and tailwinds
Slide 6: Financial Highlights
Financial Highlights
Slide 7: Financial Highlights – Q1 FY25
Financial Highlights – Q1 FY25 In ₹ Cr Q1 FY25 Q1 FY24 Q4 FY24 YoY% QoQ% Generics 659 700 719 (6) (8) Biosimilars 2,083 2,015 2,358 33 (12) Research Services 790 808 917 (2) (14) Revenue from Operations 3,433 3,423 3,917 0 (12) Total Revenue 4,5671 3,516 3,966 30 15 Core EBITDA2 903 936 1,176 (4) (2
Slide 8: Generics
Generics
Slide 9: Biocon Generics: Q1 FY25 Business Performance update
Biocon Generics: Q1 FY25 Business Performance update Overall performance for Q1 muted, but inline with expectations. Reflects Q1 Q1 Q4 pricing challenges in both APIs and formulations. In ₹ Cr YoY% QoQ% FY25 FY24 FY24 Signed an exclusive licensing agreement with Handok, South Korea for Revenue from
Slide 10: Biosimilars
Biosimilars
Slide 11: Biocon Biologics: Q1 FY25 Business Performance Update
Biocon Biologics: Q1 FY25 Business Performance Update Focus in FY25 on consolidation and leveraging unique, vertically integrated model to drive profitable growth Strong demand across product range in the US with double-digit market shares Market shares in Europe stable with strong performance in ke
Slide 12: Biocon Biologics: Q1 FY25 Financial Update
Biocon Biologics: Q1 FY25 Financial Update Q1 Q1 Q4 In ₹ Cr YoY% QoQ% FY25 FY24 FY24 Revenue grew 11% vs. last year on a like-to-like basis after adjusting Revenue from 2,083 2,0151 2,358 3 (12) for revenues in Q1FY24 from the BFI Unit, India Operations Growth driven by increase in market shares, te
Slide 13: Biocon Biologics: Q1 FY25 Regulatory Update
Biocon Biologics: Q1 FY25 Regulatory Update USFDA approved Yesafili, bAflibercept, as the 1st interchangeable biosimilar - marks our entry into Ophthalmology bDenosumab global clinical trial has met required endpoints; on- track for filings later this year EMA renews GMP Certificates of Compliance f
Slide 14: Research Services
Research Services
Slide 15: Syngene: Q1 FY25 update
Syngene: Q1 FY25 update Q1 performance inline with expectations and guidance given in Q4 FY24 Q1 Q1 Q4 Steady performance by Dedicated centers with continued growth In ₹ Cr YoY% QoQ% FY25 FY24 FY24 momentum in Biologics manufacturing driven by both commercial and clinical scale projects Revenue from
Slide 16: Concluding Remarks
Ne me : Concluding Rem Ya \ a | ay fo ‘ = es > ae % goth o - 4 : ~ 4 aa < i : ‘ in
Slide 17: Concluding Remarks: Q1 FY25
Concluding Remarks: Q1 FY25 Underlying operating performance – inline with expectations and earlier guidance Second quarter performance expected to largely mirror the first quarter performance in fiscal 2025 Expect transition to accelerated growth in the second half, underpinned by - Continued tract
Slide 18: Q&A
Q&A The Multiplier Effect MAXIMIZING VALUE